Brokerages expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to announce $1.46 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $1.39 billion to $1.53 billion. Regeneron Pharmaceuticals reported sales of $1.22 billion during the same quarter last year, which indicates a positive year over year growth rate of 19.7%. The firm is expected to issue its next quarterly earnings report before the market opens on Wednesday, November 8th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $1.46 billion for the current financial year, with estimates ranging from $5.59 billion to $5.97 billion. For the next financial year, analysts forecast that the business will report sales of $6.29 billion per share, with estimates ranging from $5.89 billion to $6.59 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, topping the consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period last year, the business earned $2.82 earnings per share.

A number of brokerages have commented on REGN. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price objective on the stock in a report on Wednesday, August 9th. Leerink Swann reaffirmed an “outperform” rating and issued a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, Robert W. Baird downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a research report on Tuesday, August 8th. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $489.92.

COPYRIGHT VIOLATION WARNING: “$1.46 Billion in Sales Expected for Regeneron Pharmaceuticals, Inc. (REGN) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/17/1-46-billion-in-sales-expected-for-regeneron-pharmaceuticals-inc-regn-this-quarter.html.

Shares of Regeneron Pharmaceuticals (REGN) traded down 0.45% on Tuesday, reaching $443.67. The company had a trading volume of 148,846 shares. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55. The firm has a market capitalization of $47.04 billion, a price-to-earnings ratio of 44.51 and a beta of 1.63. The company’s 50-day moving average price is $456.72 and its 200-day moving average price is $455.81.

In other news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Sanofi bought 166,415 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was bought at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold 89,468 shares of company stock worth $42,312,448 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

A number of institutional investors have recently modified their holdings of REGN. Fieldpoint Private Securities LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth $130,000. Sterling Investment Advisors Ltd. lifted its holdings in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares during the period. FNY Managed Accounts LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth $140,000. FNY Partners Fund LP lifted its holdings in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares during the period. Finally, Alpha Windward LLC lifted its holdings in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1 shares during the period. Institutional investors and hedge funds own 67.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.